Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

塞库金单抗 伊克泽珠单抗 医学 银屑病 阿达木单抗 中止 皮肤病科 回顾性队列研究 银屑病面积及严重程度指数 内科学 银屑病性关节炎 疾病
作者
Ying Li,Jiajing Lu,Xiaoyuan Zhong,Ying-Yuan Yu,Na Yu,Yu Wang,Yonggang Xie,Yangfeng Ding,Yuling Shi
出处
期刊:Clinical, Cosmetic and Investigational Dermatology [Dove Medical Press]
卷期号:Volume 15: 2245-2252 被引量:8
标识
DOI:10.2147/ccid.s387759
摘要

Data pertaining to biologic agents used for treating psoriasis in real-world settings are lacking at present. To compare drug survival at 52 weeks for a range of biologics used to treat psoriasis under real-world conditions.This was a retrospective, single-center, observational study of a cohort of patients diagnosed with plaque psoriasis treated using ixekizumab, secukinumab, guselkumab, or adalimumab between January 2020 and December 2021. Baseline demographic characteristics, duration of psoriasis, and prior biological treatments for all patients were recorded. Drug survival rates were analyzed in different patient groups using Kaplan-Meier curves and Log rank tests.In total, this study included 386 plaque psoriasis patients, of whom 70, 175, 36, and 105 were, respectively, treated using ixekizumab, secukinumab, guselkumab, and adalimumab. Over a 52-week period, the overall cumulative drug survival rates for ixekizumab, secukinumab, guselkumab, and adalimumab were 67.1%, 63.0%, 72.2%, and 37.1%, respectively. Lack of efficacy was the primary cause of discontinuation for these biologic therapies, followed by economic burden and adverse event incidence.These results suggest that guselkumab exhibited superior drug survival, drug survival outcomes for ixekizumab and secukinumab were comparable, and significantly better than those of adalimumab in China. Preventing a loss of drug efficacy represents a primary approach to improving biologic drug survival in psoriasis patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3应助Joy采纳,获得10
刚刚
刚刚
刚刚
1秒前
1秒前
糊涂的元容完成签到,获得积分10
1秒前
qiangdoudou完成签到,获得积分10
2秒前
zz完成签到,获得积分20
2秒前
2秒前
咩鹿酱完成签到,获得积分10
3秒前
3秒前
天宇发布了新的文献求助10
3秒前
FashionBoy应助科研通管家采纳,获得10
3秒前
大个应助科研通管家采纳,获得10
3秒前
852应助科研通管家采纳,获得10
3秒前
CodeCraft应助科研通管家采纳,获得10
3秒前
汉堡包应助科研通管家采纳,获得10
3秒前
打打应助科研通管家采纳,获得10
4秒前
脑洞疼应助科研通管家采纳,获得20
4秒前
4秒前
脑洞疼应助科研通管家采纳,获得10
4秒前
慕青应助科研通管家采纳,获得10
4秒前
浅尝离白应助科研通管家采纳,获得26
4秒前
研友_ED5GK应助科研通管家采纳,获得30
4秒前
4秒前
完美世界应助科研通管家采纳,获得10
4秒前
研友_ED5GK应助科研通管家采纳,获得30
4秒前
充电宝应助科研通管家采纳,获得10
4秒前
甜甜玫瑰应助科研通管家采纳,获得10
4秒前
高大凌寒应助科研通管家采纳,获得10
4秒前
研友_ED5GK应助科研通管家采纳,获得30
4秒前
4秒前
研友_ED5GK应助科研通管家采纳,获得30
4秒前
共享精神应助科研通管家采纳,获得10
4秒前
4秒前
桐桐应助科研通管家采纳,获得10
4秒前
6秒前
晓凡发布了新的文献求助10
6秒前
6秒前
6秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3152922
求助须知:如何正确求助?哪些是违规求助? 2804134
关于积分的说明 7857235
捐赠科研通 2461873
什么是DOI,文献DOI怎么找? 1310502
科研通“疑难数据库(出版商)”最低求助积分说明 629279
版权声明 601788